NOVAVAX (#NOVAVAX) weekly uptrend opportunity based On 1.00 Lot Calculation:
- NOVAVAX is a U.S. producer of novel, next-generation vaccines designed to prevent life-threatening infectious diseases, such as the influenza virus. They use innovative proprietary recombinant nanoparticle vaccine technology. Candidates in the company's pipeline include vaccines for seasonal and pandemic influenza, NanoFlu (Older Adults), Respiratory Syncytial virus (RSV), and ResVax (Infants via Maternal Immunization).
- EVENT I (EU): NOVAVAX is expected to submit an authorization request for its COVID-19 vaccine to the European Medicines Agency (EMA) in the third quarter of 2021 (Q3’21) (By the end of September). Novavax already has an agreement in place to supply up to 100 million doses to the European Union with an option for another 100 million doses through 2023.
- EVENT II (INDIA): The company already applied for Emergency Use Authorization for its COVID-19 vaccine in India. By October, the company’s vaccine is expected to enter India, the second-most populated country in the world.
- EVENT III (US): NOVAVAX TO SEEK AN EMERGENCY USE AUTHORIZATION FROM THE U.S. FOOD AND DRUG ADMISISTRATION (FDA) IN THE FOURTH QUARTER (Q4, 21). PREVENT-19, Novavax' study to assess the safety and efficacy of the company's recombinant nanoparticle protein vaccine, NVX-CoV2373 with Matrix-M™ adjuvant, demonstrated 90% overall efficacy and 100% protection against moderate and severe disease. NVX-CoV2373 is stored and stable at 2°-8°C, allowing the use of existing vaccine supply chain channels for its distribution. Novavax already has an agreement in place to supply up to 100 million doses to the U.S.
- VACCINE EFFICACY RATE: NVX-CoV2373 (COVID-19 VACCINE) is being evaluated in two pivotal Phase 3 trials: 1) a trial in the U.K. that demonstrated efficacy of 96.4% against the original virus strain, 86.3% against the Alpha (B.1.1.7) variant and 89.7% efficacy overall; 2) the PREVENT-19 trial in the U.S. and Mexico that demonstrated 100% protection against moderate and severe disease and 90.4% efficacy overall.
- STOCK PRICE ACTION: NOVAVAX reached an all-time high of $331.68 in February 2021, trading up by more than 100% since the beginning of the year. NOVAVAX traded last around $238, upside of 39% to its all-time high reached recently.
NOVAVAX (#NOVAVAX), September 1, 2021
Current Price: 238
|
NOVAVAX |
Weekly |
|
Trend direction |
|
|
305 |
|
|
285 |
|
|
270 |
|
|
210 |
|
|
195 |
|
|
180 |
Example of calculation base on weekly trend direction for 1.00 Lot*
|
NOVAVAX |
||||||
|
Pivot Points |
||||||
|
Profit or loss in $ |
33,500.00 |
23,500.00 |
16,000.00 |
-14,000.00 |
-21,500.00 |
-29,000.00 |
|
Profit or loss in €** |
28,341.79 |
19,881.56 |
13,536.38 |
-11,844.33 |
-18,189.51 |
-24,534.69 |
|
Profit or loss in £** |
24,355.31 |
17,085.07 |
11,632.39 |
-10,178.34 |
-15,631.02 |
-21,083.70 |
|
Profit or loss in C$** |
42,205.98 |
29,607.18 |
20,158.08 |
-17,638.32 |
-27,087.42 |
-36,536.52 |
* 1.00 lot is equivalent of 500 units
** Calculations for exchange rate used as of 12:13 (GMT+1) 01/09/2021
Fortrade recommends the use of Stop-Loss and Take-Profit, please speak to your Client Manager regarding their use.
*** You may wish to consider closing your position in profit, even if it is lower than suggested one
**** Trailing stop technique can protect the profit – Ask your Client Manager for more details